Graham Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Graham Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$871K	Buy	4,606 +3,392	+279%	+$593K	0.02%	474
2025 Q4	$206K	Buy	+1,214	New	+$186K	﹤0.01%	1029
2024 Q1	–	Sell	-5,310	Closed	-$653K	–	1183
2023 Q4	$653K	Sell	5,310 -4,109	-44%	-$513K	0.01%	509
2023 Q3	$1.22M	Buy	+9,419	New	+$1.26M	0.03%	307
2023 Q2	–	Sell	-1,783	Closed	-$261K	–	1133
2023 Q1	$261K	Buy	+1,783	New	+$264K	0.01%	906
2022 Q2	–	Sell	-3,170	Closed	-$493K	–	1130
2022 Q1	$493K	Buy	+3,170	New	+$460K	0.02%	557

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Graham Capital Management's JAZZ Position: Q1 2026 in Review

Graham Capital Management increased its Jazz Pharmaceuticals (JAZZ) stake by 279% in Q1 2026, buying an estimated $593K and bringing the position to 4,606 shares worth $871K. The position accounts for 0.02% of the portfolio, ranked #474.

Graham Capital Management first reported a position in JAZZ in Q1 2022 and has held it in 6 quarters since. The position peaked at $1.22M in Q3 2023. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Graham Capital Management held 4,606 shares of Jazz Pharmaceuticals worth $871K as of Q1 2026.
Graham Capital Management bought 3,392 Jazz Pharmaceuticals shares in Q1 2026, an estimated $593K.
Jazz Pharmaceuticals made up 0.02% of Graham Capital Management's portfolio in Q1 2026, its #474 holding.
Graham Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
Graham Capital Management's Jazz Pharmaceuticals position peaked at $1.22M in Q3 2023.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.